How T1D Exchange Integrated Multiple Data Sources to Impact Diabetes Research
T1D Exchange, a nonprofit focused on type 1 diabetes research, needed to expand beyond its own registry data. It partnered with Panalgo to use the IHD platform and real-world-evidence solutions, enabling it to "explore new data sources; link existing data with new sources; develop research questions; conduct analyses; create long term research goals." No specific numerical outcomes or quantified impacts are disclosed on the page; the full case study is behind a download.
Norstella is a holding company merging several pharma-intelligence brands — Citeline (trial intelligence), Evaluate (forecasting), MMIT (payer/formulary data) and Panalgo (real-world analytics) — into one data asset.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by Norstella on its own site — read the original case study on panalgo.com ↗
Note: Landing page; no quantified outcomes visible, gated behind download
Related use cases
- 01Empowering Early Disease Diagnosis with Real-World Data
- 02Refining Rare Disease Targeting with Real-World Data
- 03Gain Real-Time Insights on High-Risk Patient Populations with Real-World Data
- 04Powering Unbiased Outcomes Research with Longitudinal Data
- 05NorstellaLinQ: Better Together: Getting the Full Patient Picture
- 06Trial Rescue & Reconnaissance